中國生物製藥(01177.HK)MSCI ESG評級躍升至A級
格隆匯11月1日丨中國生物製藥(01177.HK)宣佈,根據國際權威指數機構MSCI(Morgan Stanley Capital International,摩根士丹利資本國際公司)最新公佈的2023年度環境、社會及管治("ESG")評級結果,基於在ESG領域的持續深耕與優秀表現,中國生物製藥獲得A級評價。這是中國生物製藥連續第三年實現評級提升,在獲評的中國醫藥行業企業中達到領先水平。
MSCI是當前全球資本市場最受關注與認可的ESG指數評級機構之一,其評級結果已成為國際資本市場的主流投資參考依據。自2021年起,中國生物製藥MSCI ESG評級連續三年由BB級穩步提升至A級。此項成績,是中國生物製藥ESG策略深度落地的有效反饋與ESG管治成效的客觀反映,也是資本市場對公司長期價值的直觀認可。
MSCI評級報吿顯示,中國生物製藥在「產品安全與質量(Product Safety & Quality)」及「醫療可及性(Access to Healthcare)」兩個關鍵議題的管理表現處於行業領先水平,並在「有害廢棄物排放(ToxicEmissions & Waste)」、「人才資本開發(Human Capital Development)」及「管治(Governance)」等議題表現亮眼,各議題得分高於行業平均得分。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.